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Abstract
Background: Most of the eukaryotic genome is transcribed, yielding a complex network of transcripts including
thousands of lncRNAs that generally lack protein coding potential. However, only a small percentage of these
molecules has been functionally characterised, and discoveries of specific functions demonstrate layers of complexity. A
large percentage of lncRNAs is located in the cytoplasm, associated with ribosomes but the function of the majority of
these transcripts is unclear. The current study analyses putative mechanisms of action of the lncRNA species member
ZFAS1 that was initially discovered by microarray analysis of murine tissues undergoing mammary gland development.
As developmental genes are often deregulated in cancer, here we have studied its function in breast cancer cell lines.
Results: Using human breast cancer cell lines, ZFAS1 was found to be expressed in all cell lines tested, albeit at
different levels of abundance. Following subcellular fractionation, human ZFAS1 was found in both nucleus and
cytoplasm (as is the mouse orthologue) in an isoform-independent manner. Sucrose gradients based on velocity
sedimentation were utilised to separate the different components of total cell lysate, and surprisingly ZFAS1 was
primarily co-localised with light polysomes. Further investigation into ribosome association through subunit
dissociation studies showed that ZFAS1 was predominantly associated with the 40S small ribosomal subunit. The
expression levels of ZFAS1 and of mRNAs encoding several ribosomal proteins that have roles in ribosome assembly,
production and maturation were tightly correlated. ZFAS1 knockdown significantly reduced RPS6 phosphorylation.
Conclusion: A large number of lncRNAs associate with ribosomes but the function of the majority of these lncRNAs
has not been elucidated. The association of the lncRNA ZFAS1 with a subpopulation of ribosomes and the correlation
with expression of mRNAs for ribosomal proteins suggest a ribosome-interacting mechanism pertaining to their
assembly or biosynthetic activity. ZFAS1 may represent a new class of lncRNAs which associates with ribosomes to
regulate their function.
Reviewers: This article was reviewed by Christine Vande Velde, Nicola Aceto and Haruhiko Siomi.
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Background
Long non-coding RNAs (lncRNAs) comprise a large
proportion of the transcribed RNA species in cells, and
are responsible for a diversity of functions [1]. Early
studies of lncRNAs showed that they are located in the
nucleus, in which they interact with different chromatin-
modifying complexes, resulting in a paradigm in which
lncRNAs regulate transcription through chromatin modi-
fication [2]. The field of lncRNA research has rapidly
expanded, and novel functions have been identified.
LncRNAs are versatile molecules that function also in the
cytoplasm where they interact with other RNA species to
regulate their processing and post-transcriptional regu-
lation, with numerous proteins to regulate their func-
tion and with ribonucleoprotein complexes to modulate
translation, either of specific genes or of protein syn-
thesis globally [3].
LncRNAs are involved in complex biological processes
such as normal development and disease pathogenesis
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[4]. Several lncRNAs are associated with known develop-
mental protein-coding genes, and many lncRNAs are
differentially expressed during induced differentiation
of embryonic stem cells [5]. Loss of function of a subset
of lncRNAs involved in embryonic development leads
to loss of pluripotency or commitment to differenti-
ation programmes [6, 7]. LncRNAs have also been iden-
tified as establishing and maintaining gene expression
patterns during the development of different tissues
and organs, including breast tissue, in which they con-
tribute to the differentiation and organisation of the
mammary epithelium [8].
Recent studies have found that a large proportion of
long non-coding RNAs, despite lacking protein-coding
potential, are associated with the ribosomes [9–11]. The
precise function of the majority of these transcripts
interacting with ribosomes remains unknown, although
those few that have been studied in detail have been
found to regulate translation by associating with the
polysomes during stress conditions and regulating the
translation of specific mRNAs, such as Uchl1AS, an anti-
sense lncRNA which regulates its protein-coding partner
UCHL1 [12]. This however is unlikely to be the main
mechanism of action of ribosome-associated lncRNAs as
few antisense lncRNAs colocalise with their protein-
coding partners [9]. Other lncRNAs associate with ribo-
somes for targeted degradation, but transcriptome-wide
studies of ribosome-mediated degradation have found
only a few lncRNAs utilising this pathway [13]. Given
the complexity of ribosomes, from their biogenesis to
their synthetic function, there are many possible avenues
by which lncRNAs could regulate ribosomal activity.
Ribosomes have long been known to be deregulated
in tumourigenesis, with a large number of tumour
suppressor genes and oncogenes modifying the trans-
lational activity of ribosomes [14].
Recent microarray analyses of tissue from mouse
mammary glands at different stages of post-pubertal de-
velopment have revealed that several lncRNAs are differ-
entially expressed in developing mammary glands [15].
Of these lncRNAs, a previously uncharacterised lncRNA
(GenBank ID AK005231) was studied, as it is differen-
tially expressed during mouse mammary gland develop-
ment and also found at the syntenic region in the
human genome. This lncRNA, Zfas1, is located on the
antisense strand of the Znfx1 (zinc finger NFX-1-type
containing) promoter region and is host to three snoR-
NAs. Further analysis of this lncRNA showed that it is
expressed in most tissues, but showed greatest abun-
dance in developing mammary glands [15]. In vivo,
Zfas1 was found to be restricted to the epithelial cells of
the mammary gland ducts and alveoli of pregnant mice.
Knockdown of Zfas1 by siRNA in a mouse mammary
epithelial cell line increased cellular differentiation
significantly and to a lesser extent induced proliferation
[15]. These experiments suggested that Zfas1 plays im-
portant roles in mammary gland development. In the
human genome the lncRNA antisense to ZNFX1 showed
similar structure to Zfas1 in mouse (Fig. 1a). Given its
role in mammary epithelial proliferation and differenti-
ation, ZFAS1 expression was compared in human inva-
sive ductal carcinoma and in normal breast tissue, and
was found to be decreased in abundance in the former
[15]. These results prompted further study of the func-
tion of ZFAS1 using human breast cancer cell lines.
According to the Mar 2006 NCBI36.1/hg18 genome
assembly, at least five different isoforms of ZFAS1 exist
[16]. They vary in size from 516 to 1006 bases with
exons two and five common to all isoforms. In the
present study, we sought to identify different isoforms
of ZFAS1 and to investigate their cellular localisation.
We confirmed that ZFAS1 is expressed as at least five
different isoforms, found in both cytoplasmic and nu-
clear compartments. We also found that cytoplasmic
ZFAS1 is localised primarily with 80S ribosomes and
light polysomes, and ribosome dissociation studies
showed that ZFAS1 is associated with the small subunit
of the ribosome. Global inhibition of ribosome activity
through growth arrest and treatment with the transla-
tion inhibitor puromycin leads to an increase of ZFAS1
content in certain cell lines. ZFAS1 expression is
strongly correlated with that of a number of mRNAs
encoding ribosomal proteins involved in ribosome bio-
genesis, and its abundance also increases upon induced
ribosome biogenesis. Knockdown of ZFAS1 decreases
the phosphorylation state of the ribosomal protein
RPS6. ZFAS1 may be involved in the regulation of the
ribosome through interactions with mature ribosomes
in the cytoplasm as well as through interactions with
immature ribosomes in the nucleus.
Results
Protein-coding potential for ZFAS1
Alternative splicing of pre-mature RNA is an important
process that increases the repertoire of mRNA isoforms.
Five different isoforms (Fig. 1a) have been reported for
ZFAS1 according to the Mar 2006 NCBI36.1/hg18 gen-
ome assembly. To ensure that the human variants of
ZFAS1 are non-protein-coding as demonstrated in mice
[15], predicted open reading frames generated from
ExPASy for each isoform were aligned against Riboseq
data derived from GWIPS-viz [17] to determine whether
predicted peptides matched those identified by riboso-
mal occupancy (Additional file 1: Figure S1). The major-
ity of the peaks corresponding to ribosomal occupancy
overlapped with genomic regions of intron-derived
snoRNAs. These peaks are a source of background RNA
in profiling experiments, similar to that of GAS5,
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another lncRNA that is host to several snoRNAs as de-
scribed by Ingolia et al. [18]. A peak in ribosomal occu-
pancy was observed in exon 2 of the ZFAS1 isoforms,
which corresponded to an open reading frame (ORF)
that predicted a peptide of 25 amino acids (M D F G R
G S H H W T S K E A T C R H L Q P S I S Stop). A
query of PeptideAtlas, a database of peptide sequences
deduced from proteomic analyses [19], showed that no
peptides have been identified that correspond to this
particular ORF. Together, these observations led us to
conclude that the human isoforms of ZFAS1 are unlikely
to encode a peptide.
Expression of ZFAS1 and ZNFX1 in breast cancer: cell line
and The Cancer Genome Atlas data
ZFAS1 is expressed in mouse mammary gland tissues,
and was previously found to be downregulated in human
invasive ductal breast carcinoma, as compared to normal
breast tissue [15]. To further analyse ZFAS1 expression
and to characterise its function, we have used breast
cancer as our model system. We performed qPCR on
cDNA prepared from 17 breast cancer cell lines, a kera-
tinocyte cell line (HaCat), a melanoma cell line (MDA-
MB-435) and two breast epithelial cell lines, Bre80hTert
and MCF10A. Different levels of expression of ZFAS1
were detected in these cell lines, as shown in Fig. 1b.
ZNFX1 was also expressed in these cell lines, and as
with previous results [15], was approximately 25 fold less
abundant than ZFAS1 (Fig. 1b). The expression levels of
ZFAS1 and ZNFX1 were not significantly correlated
(Pearson correlation coefficient, R = −0.0021, p = 0.93),
further suggesting that ZFAS1 and ZNFX1 are independ-
ently regulated (Fig. 1b). We also could not detect any
significant difference in ZFAS1 or ZNFX1 expression be-
tween ER+ (n = 9) and ER- (n = 5) cell lines (P = 0.38)
(data not shown). Many lncRNAs regulate the protein-
coding genes in cis. If this was the case with ZFAS1 and
ZNFX1, it would be expected that the abundance of
their transcripts should be related. The lack of any cor-
relation is evidence that cis regulation involving this pair
of genes does not apply, and provides a basis for seeking
alternative ZFAS1 activities.
We also analysed the genome-wide RNA transcript
profile from TCGA (breast invasive carcinoma expres-
sion) by RNAseq data set (HiSeqV2-2015-02-24) includ-
ing 1049 samples from primary breast cancers and 113
Fig. 1 Genomic orientation of ZFAS1 and ZNFX1 and their expression. a Genomic orientation of ZFAS1 in relation to ZNFX1 derived from the
UCSC Genome Browser genome assembly Mar 2006 (NCBI36/hg18). The enlarged figure of ZFAS1 shows the location of the three snoRNAs in
three consecutive introns. b Expression of ZFAS1 (left) and ZNFX1 (right) in cell lines relative to that of HPRT and GAPDH. Dark blue and dark
red bars indicate normal breast epithelial cell lines, normal coloured bars indicate breast cancer cell lines. Green and grey coloured bars indicate
non-breast cancer cell lines (MDA-MB-435 and HaCat are melanoma and keratinocyte cell lines respectively). ZNFX1 and ZFAS1 expression showed no
correlation. Expression levels were analysed in 3 biological replicates, error bars represent SEM. Primers used for qPCR are shown in panel a (forward (F)
and reverse (R) primers on exons 2 and 3 respectively)
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samples from normal breast tissue. The expression of
ZFAS1 was not significantly different in breast cancer
patients as compared to healthy controls (P = 0.4941)
as shown in Additional file 2: Figure S2A(i). However,
ZFAS1 expression was significantly reduced in basal
(p = 0.0331) and HER2 (p = 0.0011) breast cancer sub-
types (Additional file 2: Figure S2A(ii)) compared to
normal breast tissue. ER+ (n = 601) breast tumours
also displayed higher expression of ZFAS1 compared
to ER- (n = 179) negative breast tumours (p = 0.0212)
(Additional file 2: Figure S2A(iii)). Our earlier publi-
cation (2011), using a limited number of samples,
suggested that ZFAS1 expression was down-regulated
in breast cancer cells relative to normal breast epithelial
cells. Our current study sought to investigate this finding
more thoroughly, using large TCGA datasets, and found
no differences between unselected neoplastic and normal
breast samples. The possible subtle differences between
ZFAS1 expression in certain subtypes of breast cancer and
normal cells (Additional file 2: Figure S2A) could reflect
the large number of samples examined, and thus be of
minimal clinical impact.
Additional file 2: Figure S2B displays a Kaplan-Meier
plot generated from http://www.oncolnc.org of TCGA
breast cancer data set. High expressers are those 50% of
patients with the highest ZFAS1 expression, and low ex-
pressers are those 50% of patients with the lowest ZFAS1
expression. These groups do not show significant differ-
ences in survival up to 6000 days.
ZFAS1 isoforms are located in the cytoplasm
Previous experiments in mice showed that Zfas1 was
found in both cytoplasm and nucleus, whereas Znfx1
mRNA was restricted to the nucleus [15]. Since cellular
location will dictate function of lncRNA, cellular frac-
tionation was performed to identify the subcellular local-
isation of ZFAS1 in MDA-MB-468 and MDA-MB-231
breast cancer cells. Cell lysates were separated into cyto-
plasmic and nuclear fractions, total RNA extracted and
analysed by RT-PCR. ZFAS1 is present as 5 isoforms
(Figs. 1a and 2a) and primers were designed to amplify
all isoforms while allowing differentiation of these iso-
forms through product size (Fig. 2b). For the purpose of
validating the effectiveness of the fractionation proced-
ure, we used NEAT1, a nuclear lncRNA, as a nuclear
marker, and GAPDH as a positive control as it is found
in both the cytoplasm and nucleus (Fig. 2c). As indicated
for MDA-MB-468 cell extracts, ZFAS1 was found in
both the cytoplasm and nucleus, indicating that ZFAS1
is not restricted to a specific cellular compartment.
ZNFX1 on the other hand is enriched in the nucleus
(Fig. 2c) as previously reported [15]. All the isoforms of
ZFAS1 identified were present in both the cytoplasm
and the nucleus; therefore the functions of the isoforms
are not distinguishable by compartmentalisation (Fig. 2d).
No difference between the two cell lines was observed.
Identification of a ZFAS1 binding partner in cytoplasm
The functions of numerous lncRNAs have been deduced
by identifying their binding partners. To infer possible
ZFAS1 functions, we explored whether ZFAS1 was asso-
ciated with macromolecular complexes. Total cell lysate
was separated on a sucrose gradient by the principle of
velocity sedimentation. If ZFAS1 was associated with
large structures such as ribosomes or spliceosomes, it
would migrate further down the sucrose gradient. Con-
versely, if ZFAS1 was associated with small protein com-
plexes, it would remain near the top of the gradient.
Representative fractions from the gradient were
assayed for the presence of ZFAS1 molecules by RT-
PCR. ZFAS1 was found in the bottom half of the gradi-
ent, and its distribution matched regions of the A260
nm profile corresponding to the position of 80S riboso-
mal subunits and light polysomes (Fig. 3a). GAPDH, a
constitutively translated mRNA, was used as a positive
control for association with polysomes.
To distinguish ZFAS1 interactions with ribosomal com-
ponents rather than with other non-ribosomal RNA-
protein complexes, the sedimentation profile of ZFAS1
was analysed by RT-PCR after sucrose-density centrifuga-
tion in the presence of 15 mM EDTA. The sequestration
of Mg2+ by EDTA leads to dissociation of ribosomes from
mRNAs without disrupting non-ribosomal RNA-protein
complexes [20]. Figure 3b shows that EDTA treatment
disrupted the ribosome profile, leading to the loss of poly-
somes and a leftwards shift of the A260-absorbing species,
indicating that ribosomes and free mRNAs had dissoci-
ated from each other. It also leads to the loss of the
mRNA GAPDH and of the lncRNA ZFAS1 from the lower
polysome fractions and a concomitant shift of their distri-
bution to the upper fractions of the gradient. These results
indicate that the loss of ZFAS1 from the lower fractions is
due to its dissociation from ribosomes, and not from non-
ribosomal protein and/or RNA complexes (Fig. 3b), sug-
gesting that ZFAS1 is a ribosome-bound lncRNA.
Quantitative PCR (qPCR) analysis of these polysomal
fractions (Fig. 3c and d) has further highlighted the shift
of both ZFAS1 and GAPDH to upper fractions of the
gradient in the presence of EDTA as compared to con-
trol sucrose gradients. Further analysis of these polyso-
mal fractions has shown that for each ZFAS1 transcript,
there are approximately 500–20,000 transcripts of 18S
rRNA per ZFAS1, and 1000–50,000 transcripts of 28S
rRNA depending on the fraction (Fig. 3e). The data sug-
gest that ZFAS1 is associated with only a small fraction
of the ribosomes, and that it is enriched in fractions con-
taining 18S RNA relative to those containing 28S rRNA.
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ZFAS1 binds to the small ribosomal subunit
To elucidate the role of ribosome-associated ZFAS1
in regulating ribosome function, we sought to iden-
tify the subunit with which ZFAS1 was associated.
Crude ribosome pellets from MDA-MB-468 cells
were incubated with 0.5 M KCl and 1.5 mM MgCl2
buffer and separated in 15–30% sucrose gradients
[21]. Fractions from the peaks of the ribosome gradi-
ent profile corresponding to 40S and 60S subunits
(Fig. 4aai) were isolated and extracted RNA was used
for cDNA synthesis and analysis by RT-PCR. The
18S and 28S rRNA molecules were used as controls
to confirm the identity of the ribosomal subunit that
was present in particular fractions and extracted
RNA was used for cDNA synthesis and further ana-
lysis by PCR. We confirmed that ZFAS1 is predomin-
antly associated with the small ribosomal subunit
(Fig. 4aii), in an isoform-independent manner
(Fig. 4a(iii)) similar to GAPDH mRNA (Fig. 4(aiv)),
and thus is unlikely to play a role in elongation or ter-
mination of protein translation which engages the large
ribosomal subunit.
Fig. 2 Detection of ZFAS1 isoforms by RT-PCR and demonstration of their subcellular location. a Orientation of primers used in RT-PCR in relation
to ZFAS1 genomic arrangement. Primers were designed to cover all isoforms. b Primer pairs used to detect ZFAS1 isoforms and the expected PCR
product sizes for different isoforms. c Localisation of ZFAS1 and ZNFX1 in cellular compartments as detected by PCR in MDA-MB-468 cells. ZFAS1
was amplified using primer set E1F3-E5R1 and shown to be present in cytoplasm and nucleus. ZNFX1 was expressed predominantly in the
nucleus. NEAT1, a nuclear lncRNA was used as a nuclear control; GAPDH was used as a positive control. d Expression of ZFAS1 isoforms using
different primer pairs in MDA-MB-468 cellular fractions. i) E1F3-E5R1 amplified all isoforms except var1, allowing detection of var2-5. (ii) E1F3-E2R2
amplified the first exons of var2-5 in extracts of both cytoplasm and nucleus. (iii) To identify var1, PCR was performed in the first and second
exons using primer set E1F1-E2R2, and (iv) verified by internal PCR using primers E1F2-E2R1, yielding a 93 bp product in both cytoplasm and nucleus
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Fig. 3 ZFAS1 is associated with actively translating ribosomes. a Polysome distribution of MDA-MB-468 cell lysates as separated on a 7–47%
sucrose gradient. Absorbance at 260 nm is shown on the Y axis. Fractions from the top of the gradient to the bottom are shown from left to right
on the X axis. Fractions were collected in 36 equal volumes, of which every third was used for RNA extraction, and cDNA synthesised for PCR.
The presence of ZFAS1 expression was assessed using primers described in Fig. 1, with GAPDH acting as a positive control. Both species were
enriched in the bottom fractions of the gradient, corresponding to polysomes. b Polysome distribution of MDA-MB-468 cell lysate separated on a
7–47% sucrose gradient containing EDTA instead of MgCl2. Loss of the polysome peak is observed, together with a leftward shift of the ribosome
subunits. RT-PCR analysis (lower panels) showed that ZFAS1 and GAPDH are no longer enriched in the lower peaks, and show concomitant shifts
to the upper fractions. c and d Quantitative expression of ZFAS1 and GAPDH measured by qPCR relative to 18S and 28S rRNAs prepared with and
without the addition of EDTA (black graph for ZFAS1, red graph for GAPDH). ZFAS1 and GAPDH are no longer enriched in the lower fractions
corresponding to polysomes following polysome disruption by EDTA. Arrows indicate where ribosomal features are observed on profiles in
relation to fraction number. e Ratio of ZFAS1 to 18S and 28S rRNA in fractions from MDA-MB-468 polysome gradients. qPCR was performed
using samples from polysome separation and expression of ZFAS1 relative to 18S and 28S was calculated. ZFAS1 was detected in fractions
16–34 and showed greatest abundance in fraction 22, corresponding to light polysomes. The ratio of ZFAS1: 18S is also greater than that of
ZFAS1:28S for all fractions
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Further analysis in different cell lines of ZFAS1
abundance relative to that of 18S and 28S rRNA cor-
rected for dilution factor showed that the ratio of
ZFAS1:18S is greater than that of ZFAS1:28S (Fig. 4b)
with approximately 1500–8000 and 2500–50,000 18S
and 28S rRNA molecules to each ZFAS1 molecule,
respectively.
ZFAS1 expression is correlated with expression of genes
encoding proteins involved in ribosome biogenesis
Zfas1 is differentially expressed during successive stages
of mammary gland development [15]. We revisited our
original microarray data of mouse mammary gland tran-
scriptomes [15] and found that the expression of several
ribosomal protein genes was correlated with Zfas1
Fig. 4 ZFAS1 is predominantly associated with the small ribosomal subunit. a (i) Ribosomal subunit profile of MDA-MB-468 cells. The Y and X axes
represent the A260 and fraction numbers respectively. Sample 1 is from the top of the gradient while 50 is the bottom fraction. (ii) ZFAS1 RT-PCR
products using primers as described in Fig. 1 from each peak, fractions 22 and 34. 18S and 28S rRNA are used to indicate the small and large
subunit distribution in the gradient. (iii) ZFAS1 RT-PCR products using primers E1F3-E5R1 from each peak, showing that ZFAS1 is expressed with
the 40S subunit in an isoform-independent manner. (iv) GAPDH RT-PCR products from each peak, used as a positive control. b Ratio of ZFAS1 to
18S and 28S rRNA in different cell lines. qPCR was performed on extracts from various cell lines and expression of ZFAS1 relative to 18S and 28S
rRNA was calculated. Error bars represent SEM of 3 biological replicates; p values were calculated using the Mann–Whitney test
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expression during mammary gland development
(Table 1). We selected these transcripts for further
analysis of human expression data derived from
TCGA dataset as described above. The expression of
ZFAS1 was not significantly different in breast cancer
patients as compared to healthy controls (P = 0.4941),
which was the case also with RPS3 (P = 0.14) (Add-
itional file 3: Figure S3A and B).
The other ribosomal protein gene transcripts identified
in mouse mammary gland to correlate [15] with ZFAS1,
i.e. RPS21, RPS24, RPL22 and RPL28, showed significant
expression differences between normal and tumour sam-
ples (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001;
Additional file 3: Figure S3D, F, H and J). However, the
actual difference in expression between cancer and nor-
mal tissue is negligible and the significance reflects the
large sample size. The expression of these ribosomal
protein genes was strongly and positively correlated with
ZFAS1 expression in normal human tissues (Table 2,
Additional file 3: Figure S3) (Spearman correlation, r =
0.68-0.85, p > 0.001). The expression of these ribosomal
protein genes was also correlated with that of ZFAS1 in
breast cancer samples, showing moderate positive corre-
lations (r = 0.41–0.60). To confirm that this was not a
random phenomenon, genes were randomly selected and
possible correlations with ZFAS1 investigated (Additional
file 4: Table S1). These genes exhibited either weak or no
correlation with ZFAS1 indicating that ZFAS1 is specific-
ally correlated with genes encoding cytoplasmic ribosomal
proteins.
ZFAS1 increases during ribosome biogenesis
To investigate whether ZFAS1 expression changes in par-
allel with transcripts of ribosomal proteins, we induced
ribosome biogenesis in MDA-MB-468 cells by starving
them for 48 h in medium containing 0.5% serum, followed
by refeeding with medium containing 10% serum. 45S, the
pre-rRNA transcript, was used as a marker of ribosome
biogenesis. During starvation, expression of ZFAS1 and
45S remained the same as in untreated cells. At 48 h after
refeeding with serum-supplemented medium, the abun-
dance of ZFAS1 increased by 46% (p = 0.048), and of 45S
increased by 97% (p < 0.0001) (Fig. 5).
ZFAS1 knockdown: a subtle phenotype with a ribosomal
connection
The MDA-MB-468 cell line was selected for knock
down of ZFAS1 by shRNA as this cell line has moder-
ately high expression of the gene. Four different shRNAs
targeting ZFAS1 as well as a control scrambled shRNA
were used. The level of downregulation of ZFAS1
Table 1 Genes encoding ribosomal proteins, expressed
differentially during successive stages of mouse mammary gland








Rpl22 Ribosomal protein L22 −6.18
Rps24 Ribosomal protein S24 −6.007
Rps3 Ribosomal protein S3 −5.665
Rps21 Ribosomal protein S21 −5.435
Rpl28 Ribosomal protein L28 −4.577
Table 2 Correlation of ZFAS1 expression with that of ribosomal protein genes in human (i) non-tumour and (ii) breast cancer
samples (TCGA data)
ZFAS1 vs. RPS3 ZFAS1 vs. RPS21 ZFAS1 vs. RPS24 ZFAS1 vs. RPL11 ZFAS1 vs. RPL22 ZFAS1 vs. RPL28 ZFAS1 vs. MRPL16
i) Normal Tissue
Pearson r 0.7495 0.7498 0.8053 0.8 0.849 0.6846 −0.1178
P value
P (two-tailed) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.214
P value summary **** **** **** **** **** **** ns
Significant?
(alpha = 0.05)
Yes Yes Yes Yes Yes Yes No
Number of XY Pairs 113 113 113 113 113 113 113
ii) Breast tumour tissue
Pearson r 0.4639 0.6017 0.5429 0.5654 0.4913 0.4988 0.2074
P value
P (two-tailed) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P value summary **** **** **** **** **** **** ****
Significant?
(alpha = 0.05)
Yes Yes Yes Yes Yes Yes Yes
Number of XY Pairs 1049 1049 1049 1049 1049 1049 1049
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following shRNA transfection was determined by qPCR
using the scrambled shRNA to normalize the expression
level (Fig. 6a). The result confirmed that the two shRNAs
that achieved the greatest knockdown effects were ZFAS1
shRNA BC1 and BC2, which achieved reductions of
ZFAS1 to 60 and 50% respectively. These shRNA trans-
fected cell lines were chosen for further analysis.
Previous work in mouse cell lines has suggested that
ZFAS1 acts as a regulator of proliferation [15]. Using
cells transfected with ZFAS1 shRNA BC2 as described
above, we measured cell proliferation over 7 days using
the SRB assay (Additional file 5: Figure S4A). No signifi-
cant differences were observed between cells transfected
with scrambled control and ZFAS1 shRNA BC2. Trans-
fection with the scrambled control and ZFAS1 shRNA
BC2 also did not result in significant differences in cell
size (Additional file 5: Figure S4B) or global nascent pro-
tein synthesis (Additional file 5: Figure S4C).
As ZFAS1 was found associated with the small riboso-
mal subunit we postulated that ZFAS1 may regulate
ribosome activity through interactions with components
of the 40S subunit. We chose to examine ribosomal pro-
tein S6 (RPS6), one of the major proteins on the small
ribosomal subunit. It undergoes inducible phosphoryl-
ation mediated through TORC1 and promotes protein
synthesis [22]. To examine whether ZFAS1 affects the
phosphorylation state of RPS6 we performed Western
blot analysis by using total protein from cells containing
ZFAS1 shRNA BC1 and BC2 and scrambled controls
shRNA, investigating the relative abundance of phos-
phorylated RPS6 (the functionally active form) and total
RPS6 (Fig. 6bi). Knockdown of ZFAS1 decreased the
phosphorylation level of RPS6 in ZFAS1 BC1 and BC2
shRNA transfected cells by 36 and 35% respectively
(Fig. 6bii). Total RPS6 also decreased in ZFAS1 BC2
shRNA transfected cells (28%), although to a lesser ex-
tent than phospho-RPS6. When compared to BC3,
which did not decrease ZFAS1, there was no change in
either phospho-RPS6 or total RPS6 protein abundance
(Fig. 6b). The decrease in abundance and phosphoryl-
ation state of RPS6 supports the hypothesis of functional
interactions between ZFAS1 and the 40S subunit.
As ZFAS1 was induced during ribosome biogenesis,
we hypothesised that ZFAS1 may play a role in ribosome
induction. To determine whether induction of ribosome
biogenesis was affected by ZFAS1, qPCR was performed
on cells transfected with ZFAS1 shRNA BC1, BC2 and
scrambled controls after serum starvation and subse-
quent refeeding with normal medium (Fig. 6c). The
abundance of 45S increased 3-fold (p = 0.0398) in scram-
bled controls 48 h after the reintroduction of normal
medium. This response is similar to that shown by non-
transfected MDA-MB-468 cells in an earlier experiment
(Fig. 5). ZFAS1 knockdown cells displayed no significant
change in 45S abundance after serum starvation or
refeeding, a finding that supports the hypothesis of its
role in ribosome production.
ZFAS1 (variant 4) has a 5’TOP sequence and may resist
NMD
Five different isoforms of ZFAS1 have been reported
(Fig. 2a and d), of which the sequence of the 5’ end is
predicted to be repeats of pyrimidines, indicative of the
5’TOP structural motif. 5’-RACE (rapid amplification of
cDNA ends) was performed to confirm sequences indi-
cated by the current genomic assembly. Due to the GC-
rich nature of the 5’-end of exon 1, only exon 1 of vari-
ant 4 was identified (Additional file 6: Figure S5A). This
exon aligned to RefSeq Accession Number NR_003604,
March 2006 NCBI36/hg18 with a variable number of
thymidine residues at the 5’ end found in different tran-
scripts (Additional file 6: Figure S5A).
Tract of pyrimidines (TOP) at the 5’ end is character-
istic of a class of RNA targeted to the ribosome. 5’TOP
Fig. 5 ZFAS1 is induced concurrently with ribosome biogenesis. MDA-MB-468 cells were maintained for 48 h in medium containing low serum
(SS), and then refed (RF) for 24 and 48 h in medium containing serum at 10 %. qPCR was then performed to measure the expression of ZFAS1
and 45S rRNA at different time points. Fold change relative to time 0 is shown on the Y axis, and treatment time (h) shown on the X axis. Error
bars are SEM of three biological replicates, p values were calculated using Student’s t test
Hansji et al. Biology Direct  (2016) 11:62 Page 9 of 25
mRNAs encode ribosomal proteins and elongation fac-
tors, while other previously studied 5’TOP lncRNAs in-
clude transcripts containing snoRNAs in intronic
sequences. Upon inhibition of protein synthesis, these
transcripts accumulate as they are no longer able to
enter the ribosome wherein they would be degraded by
the nonsense-mediated decay (NMD) pathway [23]. As
ZFAS1 is host to three snoRNAs as well as containing a
5’TOP, we hypothesised that ZFAS1 might be regulated
by a similar pathway.
To inhibit ribosome function, cell growth was arrested
by serum starvation. As previously shown, lncRNA
GAS5 is upregulated during growth arrest [23, 24]. Total
RNA from multiple cell lines was tested to determine
the expression of ZFAS1 and GAS5, but only HEK293
and MDA-MB-231 showed significant upregulation of
Fig. 6 Effect of ZFAS1 knockdown on cell phenotype. a Four different shRNA constructs (BC1-4) designed to target ZFAS1 were transfected into
MDA-MB-468 cells. The efficiency of shRNA knockdown was analysed by qPCR in relation to a scrambled shRNA control. ZFAS1 transcripts were
knocked down to the greatest extent by shRNA BC1 and BC2, these were used for further analysis. b (i) Western blot analysis of phosphorylated
RPS6 and total RPS6 in ZFAS1 knockdown and scrambled control cells in three biological replicates. Actin was used as an internal control.
(ii) Semiquantitatve analysis of western blot results using densitometry comparison to actin. shRNA BC1–BC3 transfected cells and scrambled shRNA
were used. Error bars are SEM of three biological replicates, p values were calculated using Student’s t-test. c Cells transfected with scrambled shRNA
and ZFAS1-shRNA cells were maintained for 48 h in medium containing low serum (SS), and then refed (RF) for 48 h in medium containing serum at
10 %. qPCR was then performed to measure the expression of 45S rRNA at different time points. Expression is relative to three housekeeping genes
(3HK). Error bars are SEM of three biological replicates, p values were calculated using Student’s t test
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GAS5, with HEK293 cells showing greater accumulation
(15 fold increase) than MDA-MB-231 cells (3 fold in-
crease) at 72 and 48 h respectively. These cells, as well
as 8701BC cells, also showed a significant increase in
ZFAS1 (Additional file 6: Figure S5B). Thus, our results
suggest that the accumulation of ZFAS1 and GAS5 dur-
ing serum starvation is cell line-specific.
To further investigate the possible role of ZFAS1 in
ribosome function, we treated breast cancer cells with
the translation elongation inhibitors puromycin and cy-
cloheximide. Puromycin induced a significant increase of
ZFAS1 abundance in MDA-MB-231, HeLa and MDA-
MB-468 cells (Additional file 7: Figure S6), but no sig-
nificant differences in the abundance of ZFAS1 following
treatment with cycloheximide were detected (Additional
file 8: Figure S7). These results suggest that inhibiting ri-
bosomes at specific sites in certain cell lines induces the
accumulation of ZFAS1.
Discussion
Zfas1 was discovered as a lncRNA that is differentially
expressed during mouse mammary gland development
with the highest level detected during pregnancy [15].
Many antisense lncRNAs regulate the associated protein
coding genes in cis. The lack of correlation between
ZFAS1 and ZNFX1 expression indicates that there is no
apparent cis regulation between them, and provides a
basis for seeking alternative ZFAS1 activities. In this
study, we have shown that ZFAS1 is expressed in all cell
lines tested, although the abundance varies between cell
lines. ZFAS1 expression is not correlated with that of its
protein coding counterpart, ZNFX1 (Fig. 1b). Analysis
of TCGA data indicated that ZFAS1 expression was
not reduced in breast cancers in general (Additional
file 2: Figure S2A i), but suggested that particular
subtypes (basal, HER2-positive) show reduced expres-
sion (Additional file 2: Figure S2A ii, iii).
Studies in hepatocellular carcinoma and colorectal
cancer have found that ZFAS1 is more highly expressed
in these cancers as compared to normal tissues [25, 26],
and that higher expression of ZFAS1 is associated
with tumour metastasis and poor patient prognosis. It
has been hypothesised that ZFAS1 acts as a miRNA
sponge [25, 26]. However, we found no correlation
between ZFAS1 and previously described miRNA tar-
get genes [25, 26] in breast cancer according to
TCGA data (analysis not shown).
In our current studies, ZFAS1 was localised to both
the cytoplasm and nucleus in a non-isoform specific
manner (Fig. 2c and d), as with our previous study of
mouse mammary epithelial cells [15], in which only one
isoform was detected. Whether different isoforms in hu-
man have different functions remains to be elucidated.
Significant findings arising from this study are that
ZFAS1 isoforms are associated with ribosomes (Fig. 3)
and are bound to the small 40S subunit (Fig. 4). Many
lncRNAs appear to be ribosome-associated [9, 10]. We
found that cytoplasmic ZFAS1 is associated with actively
translating ribosomes, with light polysomes showing the
greatest concentration of ZFAS1. This suggests that
ZFAS1 is associated with only a small proportion of
ribosomes at any given time. Ribosomes exhibit het-
erogeneous composition, which is thought to evince
diverse functionality [27]. The widespread association
of lncRNAs with ribosomes contributes to this het-
erogeneity and may reflect possible mechanisms for
regulating ribosome function.
Microarray data from mouse mammary glands at dif-
ferent stages of development have shown that ZFAS1
and genes encoding several ribosomal proteins show
similar changes in expression level during pregnancy
and lactation (Table 1, Additional file 3: Figure S3).
These transcripts for ribosomal proteins, like ZFAS1, do
not exhibit appreciable differences in expression be-
tween human breast cancer and normal breast tissue
samples. They do, however, exhibit stronger correlations
with ZFAS1 in normal tissue compared to breast cancer
tissue. This may be a reflection of deregulated ribosome
function and synthesis that occurs in neoplastic cells
[28]. Interestingly, the respective ribosomal proteins
have been found to participate in ribosome synthesis as
regulators of ribosomal structure [29, 32, 33] and in for-
mation of mature rRNA [30, 31]. Induction of ribosome
biogenesis, confirmed by the increased expression of
45S, also induced expression of ZFAS1 (Fig. 5). These
findings suggest that ZFAS1 may be involved in early
stages of ribosome induction or production.
ZFAS1 is host to three C/D box snoRNAs which target
rRNA for post-transcriptional modification. snoRNAs
are often located within the introns of protein-coding
genes, many of which have functions in ribosome bio-
genesis and/or translation [34]. Additionally, at least one
of the five ZFAS1 isoforms contains a 5’TOP motif.
5’TOP function is manifested by selective unloading of
mRNAs from polysomes during repression of the cell
cycle, or recruitment to polysomes during cell prolifera-
tion or refeeding of starved cells [35]. It is possible that
lncRNAs with similar motifs also engage in regulatory
activities with ribosomes [22].
The lncRNA GAS5, like ZFAS1, is a member of the
5’TOP gene family, and hosts several snoRNAs. The
abundance of GAS5 transcripts increases during growth
arrest and it accumulates with submonosomal fractions
[23, 36] due to inhibition of NMD. However, the abun-
dance of GAS5 increased only in certain cell lines during
serum starvation, suggesting that its regulation by NMD
is cell line-specific. ZFAS1 also accumulated in certain
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cell lines during serum starvation (MDA-MB-231,
8701BC, HEK293) and with puromycin treatment (MDA-
MB-468, HeLa, MDA-MB-231), but not with cyclohexi-
mide treatment (Additional file 6: Figure S5; Additional
file 7: Figure S6 and Additional file 8: Figure S7). Serum
starvation causes global ribosomal inhibition, whereas cy-
cloheximide and puromycin target the ribosome at differ-
ent sites inhibiting elongation of polypeptide synthesis
[37, 38], and premature chain release and subsequent dis-
sociation of ribosomes [39] respectively. Such alternative
mechanisms may explain why these drugs have different
effects on ZFAS1 abundance, as the dissociation of riboso-
mal subunits may be required to release ZFAS1. Our data
suggest that the GAS5 and ZFAS1 transcripts function dif-
ferently in cells despite their similarity in structural motifs.
We sought to identify the possible functions of ZFAS1
through shRNA knockdown. We were able to achieve 40
and 50% knockdown using different shRNAs (BC1 and
BC2), and observed that upon reduced expression of
ZFAS1, phosphorylation of RPS6 decreased (Fig. 6b).
RPS6 is a component of the 40S small subunit, and
undergoes phosphorylation induced by anabolic signals.
The molecular mechanisms underlying the diverse ef-
fects of RPS6 phosphorylation on cellular and organis-
mal physiology are still poorly understood [22].
RPS6 is thought to regulate translation, proliferation
and cell size, but we did not observe appreciable dif-
ferences in ZFAS1 knockdown cells (Additional file 5:
Figure S4). However, S6 kinases, responsible for RPS6
phosphorylation, have been implicated as regulators of
ribosome biogenesis factors [39]. RPS6 also has dis-
tinct functions in the cytoplasm and nucleus. In the
cytoplasm, phosphorylation of RPS6 promotes transla-
tion of specific transcripts [40], whereas in the nu-
cleus it binds to the pre-rRNA after transcription as
part of the small subunit processome for generation
of mature 18S [41, 42]. Knockdown of ZFAS1 may
interfere with this ribosome biogenesis programme
reflected in reduced phosphorylation and abundance
of RPS6.
Knockdown of ZFAS1 abolishes increases in 45S abun-
dance after ribosome induction through serum refeeding
after prior starvation compared to scrambled control
siRNAs (Fig. 6c). This supports a role of ZFAS1 in ribo-
some biogenesis and may suggest that ZFAS1 functions
to promote 45S transcription or processing. However,
serum starvation affects a plethora of responses, and
ZFAS1 may modulate several divergent pathways.
We have shown that ZFAS1 binds to ribosomes and in
particular, the small 40S subunit. We propose a novel
function for this lncRNA, in which it is translocated to
the cytoplasm while still associated with the small ribo-
somal subunit. We suggest that ZFAS1 may not regulate
translation directly, but instead regulate ribosome
production and assembly, which adds another layer of
complexity to ribosome regulation and function.
The description of ribosome processing and synthesis
in humans has lagged far behind that of budding yeast,
due to the questionable assumption that these processes
are phylogenetically conserved. Studies in yeast experi-
mental systems may have limited applicability to mam-
malian systems as ribosome biogenesis trends towards
increased evolutionary complexity [43].
A large number of lncRNAs associate with ribosomes
and may act as possible ribosomal regulators [9–11]. Add-
itionally, multiple ribosomal factors often perform redun-
dant tasks, so investigating the function of a specific
lncRNA by knockdown may not exhibit an appreciable ef-
fect as it may be compensated by similarly redundant
lncRNAs and will require complementary approaches.
Conclusions
We propose a novel role for lncRNAs in which they as-
sociate with ribosomes and regulate their function. The
majority of lncRNAs exhibit low stoichiometry and the
association of each lncRNA with highly abundant ribo-
somes may confer fine tuning and selectivity upon ribo-
some function or synthesis. Our lncRNA of interest,
ZFAS1 is induced upon ribosome biogenesis, suggesting
a role in synthesis or assembly of ribosomes. ZFAS1
knockdown decreases RPS6 phosphorylation and ribo-
some biogenesis induction, suggesting that ZFAS1, in its
association with the 40S subunit, may not regulate trans-




Cells were sourced and cultured as described previ-
ously [44].
RNA extraction, reverse transcription, qPCR and PCR
RNA extraction has been described previously [15].
Briefly, total RNA from cultured cells was purified using
Trizol (Life Technologies). To remove genomic DNA,
total RNA was treated with DNAse I for 30 min at 37 °C
followed by incubation at 75 °C for 10 min to deactivate
DNAse I. To assess the quality and yield of RNA, absorb-
ance at 260, 280 and 230 nm was measured with a Nano-
drop 1000 spectrophotometer. The ratios of optical
density at 260/230 and 260/280 nm were ≥ 1.8 in all cases.
Random hexamers or oligo dT were used to reverse
transcribe 1 μg of RNA with M-MLV Reverse Tran-
scriptase (Sigma) according to the manufacturer’s in-
structions. Oligo-dT was used for the preparation of
cDNA used for analysis of ZFAS1 and ZNFX1 expres-
sion in breast cancer cell lines, whereas random hexam-
ers were used for the remaining experiments.
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For non-quantitative analysis, cDNA was diluted 1:20
and PCR-amplified for 30 cycles in a PCR thermocycler
(95 °C for 5 min, followed by 30 cycles of 95 °C for 30 s,
60 °C for 30 s, 72 °C for 1 min/kb, followed by 72 °C for
5 min). For PCR of exon 1, Kapa Hifi Taq was used ac-
cording to the manufacturer’s instructions with a touch
down procedure [45] (98 °C for 5 min, followed by 10 cy-
cles of 98 °C for 20 s, 75 °C for 15 s and 72 °C for 30 s
in which annealing temperature was decreased by 1 °C
each cycle). After this, PCR products were amplified by
30 cycles of 98 °C for 20 s, 65 °C for 15 s and 72 °C for
30 s). Products were visualised on a 2% agarose gel
stained with ethidium bromide. The list of primer se-
quences is provided in Additional file 9: Table S2, and
the sizes of products were estimated by running a 1 kb
ladder alongside the PCR products.
For quantitative PCR, a 1:20 dilution of cDNA was
used to measure the abundance of all transcripts studied
here except for the 18S and 28S rRNAs. In the latter
cases, 1:1000 dilutions were used. Reactions contained
SYBR Green PCR master mix (Applied Biosystems), and
primers were diluted to 8 μM. Cycling conditions are de-
tailed in ref [15]. For all qPCR data, experiments were
performed three times as biological replicates.
5′ Rapid Amplification of cDNA Ends (RACE)
RNA derived from MDA-MB-468 was converted into
cDNA as described above and tailed with poly G using
terminal transferase according to the manufacturer’s de-
scription (New England Bio labs, Cat. No. M0315S).
PCR was performed as described above using primers
AN polyC + E2R2 for 10 cycles with an annealing
temperature of 65 °C, after which 1 μL of the PCR reac-
tion was used as the template for a subsequent PCR
using AN F and E2R1 primers for 30 cycles at an anneal-
ing temperature of 65 °C. PCR samples were purified
and ligated into pGEMT Easy Vector and cloned into
E.coli cells. Colonies positive for the insert were selected
and used as a template for PCR with M13 Forward and
M13 Reverse primers. Those PCR samples which dem-
onstrated the presence of the insert were then selected
for sequencing.
Subcellular fractionation
Three 175 cm2 flasks of MDA-MB-468 or MDA-MB-
231 cells were grown to 80% confluency then trypsi-
nised, and the cells pelleted at 110 g for 5 min. The cell
pellet was washed with ice-cold phosphate-buffered sa-
line (PBS), and pelleted again. The pellet was then resus-
pended in 5 mL ice-cold fractionation hypotonic lysis
buffer (10 mM HEPES pH 8.0, 1.5 mM MgCl2, 10 mM
KCl, 0.5 mM DTT, 1x protease inhibitor (Sigma Aldrich
cat no. P8340) and incubated on ice for 5 min. Cells
were then lysed with 20 strokes of a Dounce homogeniser
using a tight pestle. The lysate was centrifuged at 228 x g
for 5 min at 4 °C.
The supernatant was retained as the cytoplasmic frac-
tion. Total cytoplasmic RNA was extracted from this
fraction using Trizol. The pellet was resuspended in
3 mL of 0.25 M sucrose containing 10 mM MgCl2, and
the extract layered over 3 mL 0.88 M sucrose, 0.5 mM
MgCl2 followed by centrifugation at 2800 x g for 10 min
at 4 °C. The supernatant was discarded and the pellet
was designated the nuclear fraction, which was then sus-
pended in 1 mL Trizol for RNA isolation. Experiments
were performed twice for biological replicates.
Polysome analysis
Polysome fractionation was performed with minor modi-
fications as described in ref [46]. In detail, twelve
175 cm2 flasks of MDA-MB-468 breast cancer cells were
grown to 80% confluency then incubated with cyclohexi-
mide (100 μg/mL) in PBS for 15 min at 37 °C before
harvesting by trypsinisation and centrifugation at 110 g
for 5 min. The cell pellet was resuspended in 2 mL poly-
some lysis buffer (20 mM HEPES pH 7.4, 15 mM MgCl2,
200 mM KCl, 1% Triton X-100 (v/v), 100 μg/mL cyclo-
heximide, 2 mM DTT, 1 mg/mL heparin) and lysed with
20 strokes of a dounce homogeniser using a tight pestle.
Lysate was cleared by centrifugation at 14,000 x g for
5 min at 4 °C. Cleared cell lysate was layered upon
7–47% (w/v) sucrose gradients, prepared as described
in ref [47] in 50 mM NH4Cl, 50 mM Tris–HCl pH 7.0
and 12 mM MgCl2 in polyallomer tubes (Beckman) and
loaded into a SureSpin™ 630 rotor and centrifuged in a
Sorvall Ultracentrifuge at 100,000 x g for 4 h at 4 °C. After
centrifugation, gradients were fractionated by securing the
ultracentrifuge tube in a clamp stand and piercing the bot-
tom of the tube with a 21G needle. Drops of the sucrose
gradients flowed at a consistent rate (approximately
300 μL per fraction) into the wells of a 96 well plate, and
absorbance measured at 260 nm using a Nanodrop 1000
spectrophotometer. RNA from every third fraction was
purified using Trizol according to the manufacturer’s in-
structions and used as a template for cDNA synthesis.
For polysome release experiments, the above protocol
was followed, except that MgCl2 was not present in the
lysis buffer or the sucrose gradient, and was replaced
with 15 mM EDTA. Both experiments were performed
twice to provide biological replicates.
Ribosome subunit separation
Eight 175 cm2 flasks of MDA-MB-468 cells were grown
to 80% confluency and the cells collected by trypsinisa-
tion followed by centrifugation. The cell pellet was re-
suspended in 2 mL lysis buffer (20 mM Tris–HCl
pH 7.5, 5 mM MgCl2, 100 mM KCl, 0.5% NP40, 10 mM
2-mercaptoethanol, 1x protease inhibitor and 100 U/mL
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RNAse inhibitor (Roche, cat no 03335 399001). Cells
were lysed with 20 strokes of a Dounce homogeniser
and cell lysate was cleared by centrifugation at 12000
x g for 20 min. One-tenth of the volume of 10% w/v
sodium deoxycholate was then added to release ribo-
somes from microsomal membranes. Cleared cell lys-
ate was layered on a 50 mL 1 M sucrose cushion in
50 mM Tris–HCl pH 7.5, 5 mM MgCl2, 100 mM
KCl, 10 mM 2-mercaptoethanol and centrifuged for
16 h at 100,000 x g in a JA-30.50Ti ultracentrifuge
rotor (Beckman Coulter). Supernatant was removed,
and the ribosome pellet was resuspended in 1 mL
ribosome buffer (5 mM Tris HCl pH 7.5, 1.5 mM
MgCl2, 50 mM KCl, 10 mM 2-mercaptoethanol). KCl
and puromycin were added to the ribosome suspension to
final concentrations of 0.5 M and 1 mM respectively, then
incubated on ice for 30 min, followed by incubation at
37 °C for 15 min. The ribosome suspension was clarified
by centrifugation for 5 min at 10,000 × g.
The cleared ribosome suspension was then layered on
a 15–30% sucrose gradient in 5 mM Tris–HCl pH 7.5,
5 mM MgCl2, 0.5 M KCl, 10 mM 2-mercaptoethanol,
then centrifuged at 30,000 x rpm in a SureSpin™ 630
rotor for 14 h. Samples were collected as detailed in
‘Polysome analysis’.
Induction of ribosome biogenesis
MDA-MB-468 cells were plated in T25 flasks at 60%
confluency. Medium was aspirated, cells washed twice
with PBS, and cells cultured with 0.5% FCS-containing
medium for 48 h. After 48 h, 10% FCS-containing
medium was added for a further 48 h.
Knockdown of ZFAS1
shRNA constructs to knock down ZFAS1 and control
empty plasmid (vector) were purchased from GeneCo-
poeia. Breast cancer cells (MDA-MB-468) were grown to
80% confluency in 6 well plates and were transfected
with 4 μg or 5 μg of DNA using Lipofectamine 3000 in
accordance with the manufacturer’s instructions. Trans-
fected cells were selected as described in ref [44].
Cell proliferation assay
To measure cellular proliferation, the sulforhodamine B
colorimetric assay was used, which measures total cellu-
lar protein to measure cell density. MDA-MB-468 cells
containing constructs for ZFAS1 shRNA and scrambled
shRNA were seeded in 96 well plates at 1500, 3000,
6000 cells per well and processed as described in ref [44]
to compare differences in cell growth. Experiments were
performed twice for biological replicates.
Cell size measurement
MDA-MB-468 cells were grown in T25 flasks at 70-80
confluency. Adherent cells were trypsinised resuspend in
1 mL of PBS and diluted 100x in saline. Cells were
counted and the size distribution determined using a
Coulter Particle Count and Size Analyser (Beckman
Coulter model Z2).
Measurement of nascent protein synthesis
Synthesis of nascent polypeptides was measured using
Click-iT® Metabolic Labelling with L-azidohomoalanine
(AHA) (ThermoFisher). Cells were plated in 96 well
plates as technical duplicates at 30,000 cells per well to
achieve 70–80% confluency. Cells were washed with
warm PBS, and the medium replaced with methionine
free DMEM+ 10% FCS and incubated at 37 °C for 1 h to
deplete methionine reserves. Cells were further incu-
bated with 40 μM of Click-iT® AHA at 37 °C for 1 h in
the dark. Cells were then washed in PBS, fixed with 4%
paraformaldehyde in PBS for 15 min, and permeabilised
with 0.25% Triton® X-100 for 15 min, after which cells
were washed in 3% (w/v) BSA in PBS. Cells were then
ready for the detection reaction with alkyne tagged de-
tection molecule. For this, cells were incubated in the
dark with 10 mM TBS, 1 mM CuSO4, 100 mM sodium
ascorbate and 10 μM Alexa Fluor®647 alkyne for 30 min.
Nascent protein synthesis was determined by the fluor-
escence of Alexa 647 using a BD FACS Vantage
Cytometer.
Western blot
Cells were lysed in buffer containing 60 mM Tris–HCl,
pH 6.8, 2% (w/v) SDS, and 20% (v/v) glycerol, and pro-
tein quantitated by BCA assay. Cell lysates containing
25 μg of protein were separated by SDS-PAGE, and
transferred to PVDF membranes (Millipore). Mem-
branes were immunoblotted with antibodies against
phospho-S6 ribosomal protein (Ser240/244) (Cell Signal-
ling Cat. No. 2215) (1:1000 for anti-phospho RPS6), total
RPS6 (Cell Signalling Cat. No. 2217) and β-actin
(1:5000) (Sigma). Protein bound primary antibody was
subsequently incubated with respective secondary anti-
body prior to membrane exposure to SuperSignal West
Pico (Thermo Scientific) for β -actin or ECL plus for
phospho-RPS6 (Thermo Scientific). Resulting bands
were detected using chemiluminescence detection system
(Fujifilm Las-3000).
Statistical analysis
Statistical analysis was performed using GraphPad
Prism. Data were analysed using Mann Whitney test,
where p < 0.05 denotes a statistically significant differ-
ence. Pearson correlation test was used for correlation
analysis.
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Growth arrest and inhibition of translation
Cells were cultured in media containing 0.5% fetal calf
serum, grown to 70-80% confluency and then washed
twice with PBS and RNA collected by Trizol extraction
at 0, 24, 48, 72 h after medium replacement. For inhib-
ition of translation experiments, cells were treated with
20 μg/mL of cycloheximide or 50 μg/mL of puromycin
for 0 to 16 h. Cells were collected and RNA extracted
and processed as described above, for cDNA synthesis
and qPCR.
Random selection of genes
Genes were randomly selected from Homo Sapien
data set using Random Gene Set Generator from
http://www.molbiotools.com/.
Reviewers’ comments
Reviewer’s report 1: Christine Vande Velde, Department
of Neurosciences, University of Montreal
Reviewer summary
This manuscript demonstrates a novel role for a long
noncoding RNa (lncRNA) called ZFAS1. The authors es-
tablish the validity of the previously made claim that
ZFAS1 is, in fact, a lncRNA, ie. there is no peptide
produced. The authors present clear evidence that
five different isoforms exist and, despite prediction
that different isoforms might exhibit different sub-
cellular localization, there is no difference between
them with regards to their nucleocytoplasmic distri-
bution. Hansji and colleagues also present good
quality data which indicates that, like some other
lncRNAs, ZFAS1 is associated with polysomes. Add-
itional data demonstrate that it is the small riboso-
mal subunit and the association of ZFAS1 to this
subunit can be triggered by growth arrest and inhib-
ition of translation (via puromycin treatment).
Lastly, it is demonstrated that siRNA-mediated
knockdown of ZFAS1 reduces phosphorylation of
the ribosomal protein RPS6 and reduces 45S rRNA,
indicating that ZFAS1 is important for ribosome
biogenesis. Overall, the quality of the individual ex-
periments is high and each is well controlled. The
interpretation of the data is accurate, with minimal/
no overstatements.
Reviewer comments
Given that the authors describe five different isoforms, I
was surprised to see them largely ignored after Fig. 2.
Thus, in Figs. 3, 4, 5 and 6, it appears that only a single
isoform has been examined. Moreover, it is unclear
which isoform(s) has been followed (ie. Which primer
pair was used in these figures?). This information should
be explicitly stated.
Authors’ response: Primer pairs for qPCR have been
specified in the Fig. 1a legend [1], and cover 4 of the 5
isoforms, so representing the majority of ZFAS1 isoforms.
Primers are restated in Fig. 3 legend.
The same primer set was used for ribosome gradients,
as stated in the legend of Fig. 4. To address the issue of
particular isoforms being excluded from consideration,
we have attached Additional file 10: Figure S8 to demon-
strate different isoforms of ZFAS1 in ribosome gradients
using primers that cover 4 of the 5 isoforms (Primer set
E1F3-E5R1).
Reviewer comments
In addition, it is unclear which isoform(s) is targeted by
the siRNAs used to demonstrate effect of ZFAS1 on 45S
and rpS6. (That only 1 of the 4 siRNAs gave a robust
knockdown could indicate that there is differential role
for the various isoforms in this process.)
Authors’ response: All siRNAs targeted exon 5, which
is common for all isoforms, as depicted in Additional
file 11: Figure S9. The shRNA should therefore target all
isoforms. shRNA sequences targeting ZFAS1 are in-
cluded in the Additional file 12: Table S3.
Reviewer comments
Also, for the sake of completeness, the authors may con-
sider evaluating the presence of the different isoforms in
the 40S containing fractions.
Authors’ response: The presence of different isoforms
has been evaluated using primer set E1F3-E5R1 as added
in Fig. 4a (iii). ZFAS1 isoforms are located with the 40S
subunit extract in a non-isoform specific manner.
Reviewer comments
The authors have focused on breast cancer cell lines,
due to previous data linking ZFAS1 to mammary gland
tissue development, and a previous report of decreased
ZFAS1 in invasive ductal breast carcinoma in humans.
The authors report here that the expression of a number
of ribosomal protein genes correlates with ZFAS1 ex-
pression during mammary gland development. However,
here ZFAS1 was not found to be significantly different
in breast cancer patients compared to healthy controls.
Despite this, there was a positive correlation between
ZFAS1 expression and a number of these ribosomal pro-
tein genes. Authors suggest this discrepancy is due to
sample size differences.
Authors’ response: The data reported in the previous
paper were derived from microdissected samples from
matched normal and IDC tissue. The RNA from stroma
was not included in sample preparation. A total number
of five samples was used. Expression patterns showed ap-
proximately two fold down-regulation with no statisti-
cally significant differences in the values. On the other
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hand, TCGA data are not derived from necessarily
matched-normal samples, and the stromal tissue was in-
cluded in expression analysis. The correlation of the ribo-
somal protein genes is strong, also due to large sample
size (n = 1043 for breast cancer samples, n = 113 for nor-
mal breast tissue samples).
However, analyses on different breast cancer subtypes,
depicted in Additional file 2: Figure S2A(ii), show that
ZFAS1 is expressed more highly in normal tissues com-
pared to basal and HER2 breast cancer subtypes. It is
also more highly expressed in ER+ compared to ER-
subtypes (Additional file 2: Figure S2A(iii)). As only 5
samples were measured [1], samples having these char-
acteristics may have been disproportionally represented
compared to TCGA samples.
The role of ZFAS1 as a potential tumour suppressor
gene may not be apparent in its expression in all sam-
ples in TCGA, but may be reflected in patient survival.
Additional file 2: Figure S2B displays a Kaplan-Meier
plot generated from http://www.oncolnc.org/ of TCGA
breast cancer data set. High expressers are those 50% of
patients with the highest ZFAS1 expression, and low ex-
pressers are those 50% of patients with the lowest ZFAS1
expression. High expressers of ZFAS1 display increased
survival up to 6000 days, which could be an indicative of
higher expression of ZFAS1 in normal samples, although
the difference is not significant.
In the microarray data presented previously we have
observed differential expression of Zfas1 and ribosomal
proteins during normal mammary gland development in
mouse. RNA samples derived for microarray analysis
were mainly isolated epithelial cells of the developing
glands (see methods in [1]). In TCGA data we did not
see any differential expression among these genes
(Additional file 3: Figure S3), however the differences
were oberved in breast cancer sybtypes compared to
normal (Additional file 2: Figure S2). Various patterns
of expression observed for these proteins in different
subtypes compares to normal. In mouse mammary
gland we have see similar pattern of expression for
and the ribosomal proteins and Zfas1 which are con-
sistance with some of breast cancer data derived from
TCGA. The two systems examinded in these papers
are identical in both species therefore some discri-
pency observed in normal mammary gland develop-
ment and human breast cancer is not unexpected.
Reviewer comments
minor comments
The connection between the breast cancer cell line
analysis and the role for ZFAS1 in ribosome biogenesis
becomes evident only on page 15, with the comment
that “deregulated ribosome function and synthesis oc-
curs in neoplastic cells.” Could be helpful to highlight
this earlier so that links between breast cancer work and
ribosomal work are evident early on.
Authors’ response: We have added sentences intro-
ducing the role of ribosomes in cancer progression in
Introduction section, page 3 lines 50-52, page 5-6 lines
106-115.
We have introduced our hypothesis implicating ribo-
some production in the background (page 3, line 50-52).
Our serum starvation data also showed the link between
ZFAS1 and ribosome (Figs. 5 and 6f).
Reviewer comments
Comments that total rpS6 is unchanged by ZFAS1
shRNA is not well supported by the representative image
provided (Fig. 6e):
Authors’ response: Western blot has been repeated.
While total RPS6 does show a decrease in knockdown
cells compared to scrambled shRNA (28%), it is less sig-
nificant than the down regulation of phospho RPS6 com-
pared to scrambled shRNA (35%). We have added
Additional file 8: Figure S7 that shows the three bio-
logical replicates of the experiment.
Reviewer comments
Discussion should be shortened and kept close to the
data at hand (it starts to ramble on page 17/18). Also, I
would suggest that the authors modify the last few sen-
tences describing what they will do/are doing for the
next studies of ZFAS1.
These details are not needed and could be presented
in a more generalized way. Abstract and Conclusion
lacks any information related to the breast cancer angle
of the story. Frequently the “.” comes before the refer-
ences. This should be corrected. (ie. it should be like this
[1]. not like this. [1])
Authors’ response: Discussion has been shortened.
References have been corrected.
Reviewer’s report 2: Nicola Aceto, Department of
Biomedicine, University of Basel
Reviewer’s summary
Hansji et al. present a well-written manuscript in which
they study the long noncoding RNA ZFAS1 in breast
cancer cells. They suggest that ZFAS1 is co-localized
with polysomes, and predominantly associated with the
small ribosomal subunit. Further, they propose a mech-
anism in which ZFAS1 is required for the production of
45S rRNA as well as for RPS6 phosphorylation in breast
cancer cells. I feel that this manuscript would benefit
from a more substantial description of the rationale for
studying ZFAS1, as opposed to any other long noncod-
ing RNA. Further, additional experiments are needed to
reinforce some of the findings (summarised below). Dis-
crepancy between TCGA and previous studies in regard
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to ZFAS1 expression in normal breast cells versus breast
cancer cells should also be addressed in greater detail.
Reviewer comments
(1) Figure 1b: in the text the authors claim that there is
“trend of higher expression of ZFAS1 in normal breast
cells”, compared to cancer cell lines. Since they only
analyze two normal cell lines (one of them having very
similar levels of ZFAS1 as compared to cancer cells),
they should avoid indicating that there is a trend. Since
no statistical significance is reached comparing ZFAS1
expression in normal versus cancer cells, I would suggest
them not to overinterpret the data in this case.
Authors’ response: This has been removed.
Reviewer comments
(2) Figure 1b: can the authors exclude (experimentally)
that the difference in expression of ZFAS1 and ZNFX1
is due to different primer efficiency? It would be more
convincing to test at least two independent primer sets
for each gene, as well as to validate the primers in con-
trolled conditions (e.g. in a setting where ZFAS1/ZNFX1
are downregulated and/or overexpressed).
Authors’ response: Primer efficiency of ZNFX1 reac-
tions is included in Additional file 13: Figure S10A and
B. Primer efficiency is the same as for ZFAS1, indicating
that differences in expression level are unlikely to be con-
tributed by the rate of amplification.
A second set of primers to investigate ZFAS1 and
ZNFX1 expression has also been designed to ensure dif-
ferent expression is not due to primers. Expression of
ZFAS1 and ZNFX1 has been evaluated in breast epithe-
lial and breast cancer cell lines using these new sets of
primers showing nearly identical patterns of expression.
Correlations of qPCR results using the original and new
primers is also shown in Additional file 13: Figure S10C.
The expression of ZFAS1 and ZNFX1 are shown in
Fig. 6a when ZFAS1 is downregulated by shRNA.
Reviewer comments
Also why is it important to determine the relative ex-
pression difference between ZFAS1 and ZNFX1?
Authors’ response: The function of lncRNA in cis has
been shown in many cases (reviewed in [2]); therefore it
is important to determine the relative expression of
ZFAS1 and ZNFX1 in the same cells. Antisense lncRNAs
are known to regulate the expression of their protein cod-
ing counterparts (acting in cis) and we wanted to deter-
mine if this was the case for ZFAS1 [3]. Discrepancy in
expression level and lack of correlation suggest that
they are not co-regulated and ZFAS1 does not regulate
ZNFX1. Additionally, lncRNAs often show low expres-
sion, so the high expression of ZFAS1 is surprising and
potentially functionally important in constitutive pro-
cesses within the cell such as ribosome biogenesis.
Reviewer comments
(3) The TCGA analysis showed no difference in ZFAS1
expression between breast cancer and normal breast tis-
sue. How do the authors interpret this discrepancy with
previous results (Askarian-Amiri et al., RNA, 2011)?
And how do they motivate their interest in elucidating
ZFAS1 biology in the context of normal breast vs breast
cancer cells? The rationale for studying ZFAS1 needs to
be better explained, in light of the TCGA results.
Authors’ response: See above comments in response to
reviewer 1.
The gene expression in stromal cells in the micro-
environment may have masked the level of gene expres-
sion of breast cancer cells.
Since developmental genes are often involved in cancer
progression, and our observation of significant down-
regulation of Zfas1 from pregnancy to lactation suggested
important developmental roles, we believe that pursuing
the function of ZFAS1 in human and investigating its role
in cancer would be challenging but worthwhile.
Reviewer comments
(4) Figure 5: the authors conclude that ZFAS1 increases
during ribosome biogenesis. However, induction of
ZFAS1 and 45S rRNA could be serum-induced, yet func-
tionally disconnected events. Since the stimulation with
10% serum has an impact on a wide variety of signaling
pathways (many of which not directly connected to ribo-
some biogenesis), the authors should at least discuss the
possible limitations of this particular experiment.
Authors’ response: This has been addressed in the dis-
cussion, page 17 (page 18, line 441-442). However, the
use of the ZFAS1 shRNA BC2 to suppress ZFAS1 abun-
dance did appear to limit the induction of 45S rRNA fol-
lowing serum refeeding (Fig. 6f ) and one interpretation of
this effect is that there are mechanistic connections be-
tween the ZFAS1 and ribosomal responses.
Reviewer comments
(5) Figure 6e: Difference in p-rpS6 is not striking, and
would deserve band quantification and at least n = 3 to
determine whether or not statistically sound. Also, the
authors should include a second shRNA (e.g. BC1) to
exclude that their results are due to off-target effects of
BC2 shRNA sequence.
Authors’ response: Multiple shRNAs targeting ZFAS1
were used individually as detailed in Fig. 6a, as well as
in combination. ZFAS1 shRNA BC2 was selected because
it most effectively knocked down ZFAS1 (to 50%), while
other shRNAs showed only 19–40% knockdown. Thus we
were unable to include a second shRNA.
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We have repeated the western blot analysis in three bio-
logical replicate and performed semi-quantification of the
results. We have shown a 35% reduction in phospho-RPS6
as shown in Additional file 8: Figure S7. We also included
second ZFAS1 shRNA BC3 to exclude the possiblilty of
false positive result.
Reviewer comments
(6) Figure 6b: here too, the authors should include a sec-
ond shRNA in their experiment.
Authors’ response: SRB assay to measure cell prolifera-
tion was repeated, using scrambled shRNA, BC2 and a
second ZFAS1 shRNA BC3. This is shown below, with no
significant difference in cellular proliferation observed
(Additional file 5: Figure S4).
(7) Given that BC2 sequence enables a 50% knock-
down of ZFAS1, wouldn’t the authors expect only a par-
tial blockage of 45S rRNA synthesis in their cells upon
expression of BC2?
Yes, blockage of 45S synthesis would be lethal. ZFAS1
down-regulation may decrease the amount of 45S pro-
duced, as shown by lack of induction of 45S upon serum
refeeding as shown in Fig. 6f.
minor comments:
Figure 6: the authors refer to ZFAS1 shRNA in two
different ways: in panels C-D-E as “ZFAS1 shRNA”, and
in panel F as “BC2 knockdown shRNA”. Authors should
instead use “ZFAS1 shRNA” throughout the text.
Authors’ response: This has been changed.
Reviewer report 3: Haruhiko Siomi, Department of
Molecular Biology, Keio University
Reviewer’s summary
In sum, results shown in the manuscript are not well
connected with each other and are preliminary.
Reviewer comments
Major comments: Recent studies have shown that a
large portion of our genome is transcribed to produce a
number of long non-coding RNAs (lncRNAs). However,
the functionality of only a small number of these
lncRNAs has been demonstrated. This manuscript con-
tinues the Askarian-Amiri lab’s analysis of Zfas1, a
lncRNA that is abundantly expressed in mouse mam-
mary glands. The authors here characterize Zfas1 in hu-
man cells. Their analyses reveal that Zfas1 transcripts
may be associated with ribosomes in the cytoplasm. The
authors show that Zfas1 may also affect both expression
levels of several mRNAs encoding ribosomal proteins
and phosphorylation levels of rpS6. These results may
suggest a model in which Zfas1 might be involved in
ribosome biogenesis through a hitherto unknown mech-
anism. Major comments: 1. The first parts of this paper
(Figs. 1 and 2) mostly repeat data already published by
the authors (Askarian-Amiri et al., RNA 2011) though,
the authors characterize the human homolog of Zfas1
here. The results shown in Figs. 3, 4, 5 and 6 are to a
large extent difficult to understand. It is often unclear
what the underlying reasoning is. I simply have a hard
time to follow the logic of these analyses. It seems as if
the authors just wanted to show what they find with
Zfas1 with no clear interpretation.
Authors’ response: Figure 1a is an image derived from
the UCSC browser in [1] and current manuscript,
though panel B has not been reported previously. We
used three cell lines in our previous article [1]. However,
to establish the connection between ZFAS1 and ZNFX1
in this manuscript, we have examined their expression
in 21 cell lines and the results presented here confirmed
that there was no correlation between the expression of
these two genes.
In our previous paper [1] the relative abundance of al-
ternate isoforms of ZFAS1 in various human tissues and
cell lines, based on exon-exon junction spanning deep
sequence tags, was indicated in Fig. 5c ([1]). In this
paper we confirm the existence of at least 5 isoforms in
breast cancer cell lines tested.
Figures 3, 4, 5 and 6
Figure 3. Experiments were performed to isolate
ZFAS1 and the molecules or supramolecular complexes
with which it might be associated. For this purpose we
used sucrose gradients and identified ZFAS1 in 80S-light
polysome fractions (Fig. 3a). To confirm the association
of ZFAS1 with ribosomes we treated the lysate with
EDTA and loaded it on the gradient. To clarify the shift
of peaks upon EDTA treatment, we have changed the
scale of the Y-axis in the revised manuscript, confirming
a clear difference between panels C and D in Fig. 3.
In Fig. 4, we identified the ribosomal subunit associ-
ated with ZFAS1. Also the ratios of ZFAS1 to 18S and
28S rRNA in different cell lines were calculated.
Figure 5 confirms that upon 45S induction, ZFAS1 is
also induced in the system as explained in page 12 of
the manuscript (refer to the section ‘ZFAS1 increases
during ribosome biogenesis’, page 12 of the manuscript).
Figure 6. We have performed shRNA knockdown in
MDA-MB-468 breast cancer cells to examine the pheno-
type arising from gene manipulation. Results showed
that there was no difference in cell proliferation, cell size
and de novo protein synthesis. However the level of
RPS6 phosphorylation is reduced in knockdown cells.
Also we have seen same pattern of gene expression for
45S rRNA in cells transfected with scrambled shRNA
(Fig. 6f, left panel) as observed for non-transfected cells
(Fig. 5) and this pattern was not detected in shRNA
transfected cells (Fig. 6f, right panel).
In summary, we have described the expression patterns
of ZFAS1 in different cancer cell lines and its association
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with ribosomes (page 8-10). We have tested the associ-
ation of ZFAS1with ribosomes following EDTA treatment
and ribosomal subunit dissociation (page 10-11). This
confirmed ZFAS1 association with the small subunit. We
have shown how ZFAS1 and 45S are co-regulated during
ribosomal biogenesis (page 11-12). Following that we used
shRNA to knockdown ZFAS1. Although we did not find
any change in growth rate or global de novo protein syn-
thesis, we showed that cells with reduced ZFAS1 content
cannot upregulate 45S as observed for non- transfected
cells, or cells transfected with scrambled shRNA. We also
showed RPS6 phosphorylation is reduced in knockdown
cells (page 12-13).
Reviewer comments
For example, the authors state in page 9 that “ZFAS1 is
associated with actively translating ribosomes (Fig. 3a).”
However, the majority of ZFAS1 cosedimented with 80S
but not with polysomes.
Authors’ response: qPCR analysis of ribosomal frac-
tions shows that ZFAS1 is associated with 80S mono-
somes and (predominantly) light polysomes, with low
association with heavy polysomes (Fig. 3c). We have
deleted the “suggesting that ZFAS1 is associated with
actively translating ribosome” and added light poly-
somes instead of polysomes in the same sentence.
Reviewer comments
In addition, the distribution profiles of Zfas1 on sucrose
density gradients with/without EDTA (Fig. 3a and b) ap-
pear very similar each other, suggesting that Zfas1 is not
associated with ribosomes.
Authors’ response: To clarify the difference in distribu-
tion of ZFAS1 in those gradients we have performed
qPCR of ZFAS1 in all samples. Depiction of EDTA-
containing gradients with an expanded y-axis scale
shows marked re-distribution from the polysomes to the
dissociated ribosomes (Fig. 3d).
Reviewer comments
Figure 4 shows that ZFAS1 is more concentrated in 40S
fractions (fraction 22) than in 60S fractions (fraction 34).
However, we aren’t assured that fraction 5 or 45, for ex-
ample, may contain Zfas1 as much as does fraction 22.
Authors’ response: The graphs in Additional file 14:
Figure S11 show ZFAS1 expression in fractions derived
from the gradient. 18S rRNA is distributed mainly near
the top half of the gradient, with 28S distributed near the
bottom half. Peaks corresponding to the 40S and 60S
subunits are highlighted in red. ZFAS1 is mainly
expressed in those fractions corresponding with the 18S
(Additional file 14: Figure S11).
Reviewer comments
2. Although the authors demonstrated that transfection
with the control and Zfas1 shRNA did not result in sig-
nificant differences in cell size or global protein synthesis
(Fig. 6), they found that knockdown of Zfas1 decreases
the phosphorylation level of rpS6. Phosphorylation of
the protein normally promotes protein synthesis. How
would they interpret these results? Does overexpression
of Zfas1 increase the phosphorylation level of rpS6?
Authors’ response: Here we tested de novo protein syn-
thesis. The role of RPS6 in protein synthesis has not been
fully resolved, with the exact function of its phosphory-
lated form still a matter of debate [4]. However, RPS6
has been found to act in the nucleus as a regulator of
ribosome biogenesis and its reduced phosphorylation fol-
lowing ZFAS1 knockdown may reflect this. The observed
change in phospho-RPS6 content may also reflect its nu-
clear function [4]. ZFAS1 is highly expressed gene, we are
not sure overexpression of it can manifest the real effect
or would be artifact.
Reviewer comments
The authors also found that Zfas1 knockdown cells dis-
played no significant change in 45S rRNA abundance
after serum starvation or refeeding, though the abun-
dance of 45S rRNA increased 3-fold in controls 48 h
after the reintroduction of normal media (refeeding).
This suggests that Zfas1 may play role in induction of
45S rRNA. The authors shall consider examining pro-
cessing and maturation of 45S rRNA because Zfas1 is
present in the nucleus as well.
Authors’ response: Ribosome biogenesis may well include
processing and maturation of precursor rRNA transcripts.
We fully acknowledge the potential importance of these
processses and are currently performing more experiments
to consider the suggested functions. Also in this manuscript
we have mainly focused on cytoplasmic ZFAS1.
1. Askarian-Amiri ME, Crawford J, French JD, Smart
CE, Smith MA, Clark MB, Ru K, Mercer TR, Thompson
ER, Lakhani SR et al: SNORD-host RNA Zfas1 is a
regulator of mammary development and a potential
marker for breast cancer. RNA 2011, 17(5):878-891.
2. Guil S, Esteller M: Cis-acting noncoding RNAs:
friends and foes. Nat Struct Mol Biol 2012, 19(11):1068-
1075.
3. Villegas VE, Zaphiropoulos PG: Neighboring gene
regulation by antisense long non-coding RNAs. Int J
Mol Sci 2015, 16(2):3251-3266.
4. Meyuhas O: Chapter 1 Physiological Roles of
Ribosomal Protein S6: One of Its Kind. In: Inter-
national Review of Cell and Molecular Biology. vol. Vol-
ume 268: Academic Press; 2008: 1-37.
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Reviewer’s report 1: Chritine Vande Velde, Department of
Neurosciences, University of Montreal
Reviewer summary and comments
The authors have mostly addressed my previous con-
cerns and is improved. However, that the ZFAS1 shRNA
effect on rpS6 levels/phosphorylation is evident with
only one of the two shRNA sequences attempted is a
definite weakness of the manuscript. While the authors
have explained there are technical limitations here, this
data point is rather central to their final conclusion that
ZFAS1 may represent a new class of lncRNAs which
regulate their function. This caveat should be made ob-
vious one page 13 and the discussion.
Authors’ response: We have addressed this issue and
now have replicated the effect of shRNA by using two in-
dependent shRNAs (BC1 and BC2). We have shown the
data in Fig. 6.
Minor comment
The supplemental figures are presented out of order.
Authors’ response: We have corrected the order for
the Figures.
Reviewer’s report 2: Nicola Aceto, Department of
Biomedicine, University of Basel
Reviewer comments
(1) It is unclear to me what is the conclusion of the para-
graph “Expression of ZFAS1 and ZNFX1 in breast cancer”.
What do the authors conclude, other that ZFAS1 and
ZNFX1 are expressed in both normal and cancer?
Authors’ response: It is believed that many lncRNAs
regulate closely linked protein-coding genes in cis. If this
was the case with ZFAS1 and ZNFX1, it would be expected
that the transcript abundance of the two genes should be
correlated, either negatively (if ZNFX1 was suppressed by
ZFAS1) or positively (if it was induced). The lack of any
correlation is evidence that cis regulation involving this
pair of genes does not apply. Such a conclusion provides a
basis for seeking ZFAS1 effects at other locations and on
other processes. Our report describes our search for alter-
native mechanisms, using an unbiased approach that did
not rely on any preformed hypothesis.
We have added “Many lncRNAs regulate the protein-
coding genes in cis. If this was the case with ZFAS1 and
ZNFX1, it would be expected that the abundance of
their transcripts should be related. The lack of any cor-
relation is evidence that cis regulation involving this pair
of genes does not apply, and provides a basis for seeking
alternative ZFAS1 activities” (page 8, lines 178-182).
Also in discussion added “Many antisense lncRNAs
regulate the associated protein coding genes in cis. The
lack of correlaton between ZFAS1 and ZNFX1 expres-
sion indicates that there is no apparent cis regulation
between them, and provides a basis for seeking alterna-
tive ZFAS1 activities” (page 15-16, lines 372-376).
Reviewer comments
Additionally, expression differences between normal and
basal or HER2-positive breast cancer, despite significant,
are almost invisible. Same for ER- vs ER1. A statement
at the end of this paragraph is needed to summarize
what did we learn from these analyses.
Authors’ response: Our earlier publication (2011),
using a limited number of samples, presented prelimin-
ary evidence that ZFAS1 expression was down-regulated
in breast cancer cells relative to normal breast epithelial
cells. Our current study sought to investigate this poten-
tially important finding more thoroughly, using the
wealth of TCGA data now available. We have reported
the results of our analysis, which found minimal differ-
ences between unselected neoplastic and normal breast
samples, but which suggested that there may yet be sub-
tle differences between ZFAS1 expression in certain sub-
types of breast cancer and normal cells (Additional file 2:
Figure S2A). Thus our current analysis indicates that the
original finding needs to be reinterpreted with caution. It
leaves open the possibility that there may be subtype-
specific effects on ZFAS1 regulation or activity.
We have added “Our earlier publication (2011), using
a limited number of samples, suggested that ZFAS1 ex-
pression was down-regulated in breast cancer cells rela-
tive to normal breast epithelial cells. Our current study
sought to investigate this finding more thoroughly, using
large TCGA datasets, and found no differences between
unselected neoplastic and normal breast samples. The
possible subtle differences between ZFAS1 expression in
certain subtypes of breast cancer and normal cells (Add-
itional file 2: Figure S2A) could reflect the large number
of samples examined, and thus be of minimal clinical
impact.” (Page 9, lines 191-197).
Reviewer comments
(2) ZFAS1 and ZNFX1 primer efficiency: the authors
have now included a second primer set to demonstrate
that primer efficiency for ZFAS1 and ZNFX1 is similar,
and the data is convincing. However, in the revised ver-
sion of the manuscript they literally paste an excel sheet
with lots of numbers as Additional file 13: Figure S10A
and B. Clearly, “undigested” excel sheets are not meant
to be pasted as figure panels, and it would be better to
have a clearer figure that summarizes the data in a more
compact form.
Authors’ response: We provided the unprocessed data
to satisfy the referee’s concerns regarding primer effi-
ciency, but did not provide a more refined depiction of
the data because such preliminary characterisations are
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routine and not usually published. However, we have re-
place Additional file 13: Figure S10.
Reviewer comments
(3) I am still unconvinced about the explanation of the
rationale for dissecting the biology of ZFAS1 in the con-
text of normal vs neoplastic breast cells. The authors
claim that ZFAS1 might be seen as a developmental
gene (given its downregulation from pregnancy to lac-
tation), and since many developmental genes are in-
volved in cancer, it is worthwhile to investigate
ZFAS1 in the context of cancer cells. This view is a
bit simplistic and not very convincing at this stage,
can the authors explain better and provide a stronger
rationale that will help the reader understand the
main reasons for investigating this gene?
Authors’ response: We identified ZFAS1 in neoplastic
and normal mammary epithelium, in a study that
largely involved murine tissues. Because it is a novel
transcript, and (for a lncRNA) very highly expressed, we
sought to follow up this work in human neoplastic and
normal breast cells as we did preliminary experiments in
our previous paper in 2011. Here we extended the previ-
ous study and investigated functions of ZFAS1 in breast
cancer cell lines. Indeed there are many reports that par-
ticular lncRNAs contribute to neoplastic behaviour
(reviewed for breast cancer, reference 8). The association
between developmental and cancer genes are also well
accepted in the literature [1-4]. During the course of our
work, others have reported investigations on ZFAS1 in
different cell types (including cancer cells,) and have de-
scribed mechanisms of action that do not seem to pertain
to the cell type we are investigating. Our approach is thus
an unbiased, methodical investigation of ZFAS1 activity
in breast cells. We report that the data describing the
relative expression in cancer and non-cancer tissues are
more nuanced than first described. But there do appear
to be differences between cancer and normal cells in
ZFAS1 expression relative to that of coding genes associ-
ated with ribosomes (see the gradients of the regression
lines Additional file 3: Figure S3C, E, G and K). We an-
ticipate that the significance of these differences will be-
come apparent as ZFAS1 action is elucidated.
Reviewer comments
(4) P-S6 data in Fig. 6e/Additional file 8: Figure S7: re-
vised data does not provide evidence that P-S6 nor total
S6 are decreased as a consequence to ZFAS1 knock-
down. First, it looks like bands in Fig. 6e have been cut/
pasted from different experiments, therefore not suitable
for publication. Second, the authors do not have a sec-
ond independent ZFAS1 shRNA that shows a similar re-
sult, therefore off-target effects cannot be ruled out
(BC3 clearly shows no difference in band density,
strongly arguing that results obtained with BC2 are ra-
ther due to off-target effects). The authors are urged to
either remove any claim on P-S6 and total S6, or to
identify additional shRNAs that effectively suppresses
ZFAS1 levels to test their hypotheses on P-S6.
Authors’ response: We have provided a whole uncut
immunoblot image to address the concern that Fig. 6e
was a composite (Additional file 8: Figure S7 in previ-
ous submission). In the revised manuscript, we have
included the full image of western blots for three
shRNAs (BC1, BC2 and BC3). The differences between
scrambled and knockdown shRNAs are also presented
in the new version of Fig. 6.
We have added comments about shRNAs in page 14,
line 325-330.
Reviewer comments
(5) Accordingly to point 5, authors should remove all
claims in the manuscript that are sustained by only one
shRNA. In these cases, ZFAS1-specific effects cannot be
distinguished from off-target effects.
Authors’ response: We have performed the western blot
analysis for a second shRNA BC1, and have shown sig-
nificant down-regulation for phosphorylated RPS6. Also
performed serum starvation and refeeding experiment for
shRNA BC1 and confirmed similar result to shRNA BC2,
Fig. 6 has been modified accordingly.
Reviewer’s report 3: Haruhiko Siomi, Department of
Molecular Biology, Keio University
I will not describe the main achievements of the paper,
since this was done in the review of the original submis-
sion. In the previous review, I was not convinced that
ZFAS1 is associated with ribosomes.
On the whole it has been improved and the authors
have experimentally addressed many of the reviewers con-
cerns. However, I am still not convinced that ZFAS1 is as-
sociated with ribosomes. Additional file 1: Figure S1
shows that levels of ribosome binding to ZFAS1 tran-
scripts are similar to those observed in background
controls.
Authors’ response: Additional file 1: Figure S1 is based
on ribosome profiling studies performed by Ingolia et al, a
technique that involves digesting RNA and sequencing the
portion bound to ribosomes to give a profile of ribosome oc-
cupancy. Therefore, it only represents RNAs that are being
actively translated. As ZFAS1 is a non-coding RNA and is
not translated, the lack of peaks in the ribosome profile is
expected. It shows a similar profile to GAS5, a well-studied
ribosome-associated long non-coding RNA. This has been
addressed in Results section, “Protein Coding Potential of
ZFAS1” and is quoted below:
“The majority of the peaks corresponding to ribosomal
occupancy overlapped with genomic regions of intron-
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derived snoRNAs. These peaks are a source of back-
ground RNA in profiling experiments, similar to that of
GAS5, another lncRNA that is host to several snoRNAs
as described by Ingolia et al” (page 7, lines 154-157).
Reviewer’s comment
Figure 3a & b show that EDTA treatment, which dissoci-
ates ribosomes to ribosomal subunits, does not result in
cosedimentation of ZFAS1 with large or small ribosomal
subunits. Indeed, sedimentation profiles of ZFAS1 on su-
crose density gradients with/without EDTA appear very
similar, though the intensity of each band of ZFAS is re-
duced in B (with EDTA). Fig. 3d shows re-distribution of
ZFAS1 from the “light polysomes” to the dissociated ri-
bosomes. However, this re-distribution deserves band
quantification and at least n = 3 to determine whether or
not statistically sound. Comparing the distributions of
GAPDH in Fig. 3b and d may lead one to wonder what
the basis is for some of the major claims.
Figure 3a and b represent sucrose gradients without
and with EDTA treatment, respectively. In this experi-
ment, we asked whether ZFAS1 associates with ribo-
somes in a manner that is similar to mRNAs. Upon
EDTA treatment, the RNA associated with ribosomes
would be released due to subunit dissociation. In Fig. 3c,
we see the association of ZFAS1 starting from fraction
15, peaking in fraction 23, and ending at fraction 28.
These fractions would relate to 80S ribosomes and the
left hand of the polysome peak in Fig. 3a. On the other
hand, GAPDH association starts from fraction 23 and
ends at 35, which relates to the polysome fractions in
panel A. ZFAS1 is found in fractions 10-23 in the
EDTA-treated sample which relates to the ribosome sub-
units peak in panel B. GAPDH is found in similar frac-
tions at higher abundance. A similar result was obtained
in a second experiment and is presented in Additional
file 15: Figure S12. These data confirmed the association
of ZFAS1 with ribosomes in a similar manner to
GAPDH (mRNA), though ZFAS1 appeared in lighter
fractions. Since we cannot clearly define the 60S and 80S
peaks in Fig. 3b, we used different approaches to separ-
ate the subunits and examine the association of ZFAS1
with each subunit (Fig. 4).
We have treated samples with EDTA twice (data pre-
sented in Fig. 3 and Additional file 15: Figure S12).
Comparing these results statistically is not possible, due
to the nature of gradient collection, which inevitably
produces variations in fraction numbers between differ-
ent sucrose gradients. Therefore we have presented the
results of both experiments in their entirely.
We also treated MDA-MB-468 cells with puromycin
which serves as an acceptor of the growing peptide
chain from the P-site, forming polypeptide-puromycin
derivatives, and subsequently leading to premature
termination and subunit dissociation. We treated cells
with puromycin for different purposes, and our 30
min treatment did not achieve full subunit dissoci-
ation. Nevertheless, these conditions resulted in a par-
tial redistribution of ZFAS1 from heavier fractions to
lighter ones (Additional file 16: Figure S13). The shift
of GAPDH was more pronounced than that for
ZFAS1, suggesting that ZFAS1 release may need lon-
ger treatment. This experiment addresses our initial
question, and shows that ZFAS1 is associated with ri-
bosomes, as is the mRNA for GAPDH, although it is
found in 80S monosomes and in ligher polysomes.
Reviewer’s comment
In Response to Reviewers, the authors state that “The
graphs in Additional file 14: Figure S11 show ZFAS1
expression in fractions derived from the gradient.”
However, Additional file 14: Figure S11 does not show
such data. Additional file 15: Figure S12 shows that
most ZFAS1 cosediments with fraction 17 but not with
fraction 23/40S small ribosome subunits. If I under-
stand right, 28S rRNA is not even associated with 60S
fraction in their experiments!"
In our previous response we intended to refer to Add-
itional file 15: Figure S12 not Figure S11. This was a typ-
ing mistake. In Additional file 14: Figure S11 (current
version), red bars indicate 40S and 60S peaks. The arrow
indicating the 60S peak for 28S rRNA had been posi-
tioned wrongly in the previous version (Additional file
15: Figure S12), and this has now been amended, con-
firming that 28S is indeed associated with the 60S frac-
tion (Additional file 14: Figure S11). We thank the
Reviewer for carefully perusing our manuscript and for
alerting us to these errors.
Authors’ minor changes:
Additional file 5: Figure S4 is edited.
Figure S4-S7 in the previous revision is now presented
as Figure Additional file 6: Figure S5; Additional file 7:
Figure S6; Additional file 8: Figure S7 and Additional file
10: Figure S8.
Figure S8 in the previous revision is now deleted and
the data presented in Fig. 6.
Figure S11 is deleted and data presented in Additional
file 5: Figure S4-edited.
Table S1 and S2 are swapped in new version.
We have shortened the first paragraph of the discussion.
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Additional files
Additional file 1: Figure S1. ZFAS1 is unlikely to encode a protein.
Ribosome occupancy derived from multiple ribosome profiling
studies according to the GWIPS database is mapped to ZFAS1. Red
peaks from ribosome profile indicate the level of ribosome
occupancy whereas green peaks from mRNA seq coverage indicate
the level of transcription of a particular gene region. ZFAS1 is
indicated in blue, with numbers indicating nucleotide number for
each exon above the gene layout. Potential open reading frames,
shown in pink, were predicted using ExPASy and mapped to the
genomic layout of ZFAS1. Peaks corresponding to ribosome
occupancy were then overlaid with ORFs, with the peaks mapping
to snoRNAs in the intronic regions of ZFAS1. (PDF 271 kb)
Additional file 2: Figure S2. Analyses of ZFAS1 in breast cancer
samples derived from TCGA. A(i) Expression of ZFAS1 in normal breast (n
= 113) and breast cancer (n = 1069) samples. (ii) Expression of ZFAS1 by
tumour subtype based on PAM50 classification. ZFAS1 is more highly
expressed in normal tissues compared to basal and HER2 breast cancer
subtypes. (iii) Expression of ZFAS1 in ER+ (n = 601) and ER- (n = 179)
breast cancer samples. Unpaired Student’s t-test showed that ZFAS1 was
differentially expressed according to estrogen status. (B) Kaplan-Meier plot
generated from http://www.oncolnc.org/ of TCGA breast cancer data set.
High expressers are those 50 % of patients with the highest ZFAS1 expres-
sion, and low expressers are those 50 % of patients with the lowest ZFAS1
expression. High expressers of ZFAS1 do not show altered survival up to
6000 days. (C) Gene expression of candidate ribosomal proteins by tumour
subtype based on PAM50 classification. Unpaired student’s t-test relative to
normal tissue samples was used to calculate P values. (PDF 475 kb)
Additional file 3: Figure S3. Expression of ZFAS1 in breast cancer tissue
derived from TCGA. (A) Expression of ZFAS1 in tumour and non-tumour
samples. (B-K) Expression of concordantly regulated ribosomal protein
genes in breast cancer and normal breast tissue (TCGA data). Correlation
of the abundances of these gene transcripts to that of ZFAS1 is plotted in
the right panels for normal breast tissue and breast cancer samples. Stu-
dent’s t test was used to determine the significance of difference in ex-
pression between tumour (T) and non-tumour (N) samples, *, **, ***
represent p values of >0.05, >0.005 and >0.001 respectively. (PDF 596 kb)
Additional file 4: Table S1: Correlation of ZFAS1 expression with that
of randomly selected genes in human (i) non-tumour and (ii) breast
cancer samples (TCGA data). (DOC 38 kb)
Additional file 5: Figure S4. Effect of ZFAS1 knockdown on cell
phenotype. (A) Proliferation rates of cells transfected with vectors
expressing control (scrambled RNA) and ZFAS1-specific shRNA BC2 and
BC3 as determined by SRB assay. Error bars are SEM, n =2. (B) Size of cells
expressing control (scrambled) and ZFAS1-specific shRNA BC2 was
determined using a Coulter electronic particle counter. (C) Nascent
protein synthesis as quantified by uptake of the fluorescent amino acid
analogue, Click-iT® AHA, in ZFAS1 knockdown BC2 and scrambled control
cells, n = 2. (PDF 451 kb)
Additional file 6: Figure S5. ZFAS1 has a 5’TOP sequence and may
resist NMD. (A) Sequence of the 5’ region of human ZFAS1 as determined
by 5’RACE aligned against ZFAS1, variant 4 from NCBI136/hg138
assembly. (B) Effect of serum starvation on the abundance of ZFAS1 and
GAS5. Different cell lines were used to examine the effect of serum
starvation for up to 72 h. qPCR was performed using total RNA extracted
from each cell to measure the level of ZFAS1 and GAS5. 18S and 28S
rRNA transcripts were used to normalise the expression of ZFAS1 and GAS5.
Fold change relative to time 0 is shown on the Y axis, and treatment time
(h) shown on the X axis. Error bars are SEM of three biological replicates, p
values were calculated using Student’s t test. (PDF 471 kb)
Additional file 7: Figure S6. Effect of puromycin, a translational
inhibitor, on the abundance of ZFAS1 and GAS5. Relative expression of
genes was measured by qPCR using total RNA extracted from each cell.
18S and 28S rRNA transcripts were used to normalise the expression of
ZFAS1 and GAS5. The Y axis represents the fold change relative to time 0.
The X axis shows treatment time. Error bars are SEM of three biological
replicates, p values were calculated using Student’s t test. (PDF 172 kb)
Additional file 8: Figure S7. Effect of cycloheximide, a translational
inhibitor, on the abundance of ZFAS1 and GAS5. Relative expression of
genes was measured by qPCR using total RNA extracted from each cell.
18S and 28S rRNA transcripts were used to normalise the expression of
ZFAS1 and GAS5. The Y axis represents the fold change relative to time 0.
The X axis shows treatment time. Error bars are SEM of three biological
replicates, p values were calculated using Student’s t test. (PDF 136 kb)
Additional file 9: Table S2. List of primers used in these experiments.
The sequences are 5′ to 3′. (DOC 43 kb)
Additional file 10: Figure S8. ZFAS1 is associated with actively
translating ribosomes in an isoform-independent manner. (A) Polysome
distribution of MDA-MB-468 cell lysates as shown in Fig. 3. Fractions from
the top of the gradient to the bottom are shown from left to right on
the X axis. Fractions were collected in 36 equal volumes, of which every
third was used for RNA extraction, and cDNA synthesised for PCR. The
presence of ZFAS1 expression was assessed using primers E1F3-E5R1, with
GAPDH acting as a positive control. The presence of three bands confirms
at least 4 out of five isoforms are present in each fraction. (PDF 1333 kb)
Additional file 11: Figure S9. Genomic orientation of ZFAS1 and four
shRNA used in these experiments. (PDF 127 kb)
Additional file 12: Table S3. List of sequences of shRNA used to target
exon 5 of ZFAS1. (DOC 27 kb)
Additional file 13: Figure S10. Primer efficiency of ZFAS1 and ZNFX1.
A) The primer efficiency test for the primers used in the experiments. B)
Slopes of standard curve indicate PCR efficiency for ZFAS1 and ZNFX1
primers sets. The X axis represent the log of dilution. Y axis shows Ct
values. C) Correlation between the expression of ZFAS1 and ZNFX1 in two
different primer sets in panel of cell lines (PDF 317 kb)
Additional file 14: Figure S11. The presence of ZFAS1, 18S and 28S
expression were assessed by qPCR using fractions derived from
dissociated ribosomes (Fig. 4i). Red bars show the samples derived from
the peak of the graph in Fig. 4Ai for 40S and 60S subunit. (PDF 235 kb)
Additional file 15: Figure S12. ZFAS1 is associated with actively
translating ribosomes. (A) Polysome distribution of MDA-MB-468 cell lysates
as separated on a 7–47 % sucrose gradient. Absorbance at 260 nm is shown
on the Y axis. Fractions from the top of the gradient to the bottom are
shown from left to right on the X axis. Fractions were collected in 36 equal
volumes, of which every third was used for RNA extraction, and cDNA
synthesised for PCR. (B) Polysome distribution of MDA-MB-468 cell lysate
separated on a 7–47 % sucrose gradient containing EDTA instead of MgCl2.
Loss of the polysome peak is observed, together with a leftward shift of the
ribosome subunits. (C) and (D) Quantitative expression of ZFAS1 and GAPDH
measured by qPCR relative to 18S and 28S rRNAs prepared with and without
the addition of EDTA. Arrows indicate where ribosomal features are
observed on profiles in relation to fraction number. (PDF 536 kb)
Additional file 16: Figure S13. ZFAS1 is associated with actively
translating ribosomes. (A and B) Polysome distribution of MDA-MB-468
cell lysate derived from cells treated with and without puromycin as
separated on a 7–47 % sucrose gradient. Absorbance at 260 nm is shown
on the Y axis. Fractions from the top of the gradient to the bottom are
shown from left to right on the X axis. Fractions were collected in 36
equal volumes, of which every third was used for RNA extraction, and
Hansji et al. Biology Direct  (2016) 11:62 Page 23 of 25
cDNA synthesised for PCR. (C and D) Quantitative expression of ZFAS1
measured by qPCR from fractions collected from 7–47 % sucrose
gradient. The result present the abundance of ZFAS1 in control (untreated)
and cells treated with puromycin for 30 min. ZFAS1 peak is shifted toward
left in puromycin treated cells. (E and F) Quantitative expression of GAPDH
measured by qPCR, from fractions collected from 7–47 % sucrose gradient.
The result present the abundance of GAPDH in control (untreated) and cells
treated with puromycin for 30 min. GAPDH peak is shifted toward left in
puromycin treated cells. Left and right boxes are presenting results from
two independent experiments. (PDF 248 kb)
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